WO2019183381A2 - Short conjugated oligoelectrolytes and uses thereof - Google Patents

Short conjugated oligoelectrolytes and uses thereof Download PDF

Info

Publication number
WO2019183381A2
WO2019183381A2 PCT/US2019/023411 US2019023411W WO2019183381A2 WO 2019183381 A2 WO2019183381 A2 WO 2019183381A2 US 2019023411 W US2019023411 W US 2019023411W WO 2019183381 A2 WO2019183381 A2 WO 2019183381A2
Authority
WO
WIPO (PCT)
Prior art keywords
coe
alkyl
independently
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/023411
Other languages
English (en)
French (fr)
Other versions
WO2019183381A3 (en
Inventor
Guillermo Bazan
Zichao ZHANG
Alex MORELAND
Michael J. Mahan
Douglas M. Heithoff
Jakkarin LIMWONGYUT
Chenyao NIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to CN201980031110.5A priority Critical patent/CN112154212A/zh
Priority to US17/040,320 priority patent/US11713318B2/en
Priority to SG11202009242RA priority patent/SG11202009242RA/en
Priority to EP19772107.9A priority patent/EP3768849A4/en
Priority to JP2020551278A priority patent/JP7362131B2/ja
Publication of WO2019183381A2 publication Critical patent/WO2019183381A2/en
Publication of WO2019183381A3 publication Critical patent/WO2019183381A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application relates to antimicrobial or bactericidal conjugated oligoelectrolyte compounds (COEs), and more specifically to molecules with a high efficacy toward both Gram-negative and Gram-positive bacteria and a low toxicity toward mammalian cells.
  • COEs antimicrobial or bactericidal conjugated oligoelectrolyte compounds
  • a pharmaceutical composition that can include an effective amount of a compound described herein, such as a compound of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5, Formula 6, Formula 7, Formula (I), Formula (II), Formula (III), Formula (IV) and/or Formula (V), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt of any of the foregoing; and a pharmaceutically acceptable carrier, diluent, or excipient, wherein Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt of any of the foregoing, are as provided in the section entitled“Further Formulae.”
  • a compound described herein such as a compound of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5, Formula 6, Formula 7, Formula (I), Formula (II), Formula (III), Formula (IV) and/or Formula (V), or a pharmaceutically acceptable isomer, racemate
  • Some embodiments described herein relate to a method of treating, reducing the severity of, and/or slowing the progression of a bacterial infection in a subject in need thereof, that can include administering an effective amount of a compound of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5, Formula 6 and/or Formula 7, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt of any of the foregoing, or a pharmaceutically acceptable composition comprising the same.
  • COEs compositions based on conjugated oligoelectrolytes
  • the compounds include water-soluble molecules characterized by a hydrophobic interior fragment and side groups containing charged groups, such as cationic groups.
  • Figure 1 depicts a schematic of the synthesis of 3,5-bis((8- bromooctyl)oxy)benzaldehyde.
  • Figure 2 depicts a schematic of the synthesis of l,3-bis((8-bromooctyl)oxy)-5- vinylbenzene from 3,5-bis((8-bromooctyl)oxy)benzaldehyde.
  • Figure 3 depicts a schematic of the synthesis of (E)-l,2-bis(3,5-bis((8- bromooctyl)oxy)phenyl)ethene from 1 ,3-bis((8-bromooctyl)oxy)-5-vinylbenzene.
  • Figure 4 depicts a schematic of the synthesis of (E)-l,2-bis(3,5-bis((8- iodooctyl)oxy)phenyl)ethene from (E)-l ,2-bis(3,5-bis((8-bromooctyl)oxy)phenyl)ethene.
  • Figure 5 depicts a schematic of the synthesis of COE2-2C-C8.
  • Figure 6 depicts a schematic of the synthesis of 3,5-bis((4- bromobutyl)oxy)benzaldehyde.
  • Figure 7 depicts the synthesis of 3,5-bis((4-iodobutyl)oxy)benzaldehyde.
  • Figure 8 depicts the synthesis of l,4-bis((E)-3,5-bis(4-iodobutoxy)styryl)benzene.
  • Figure 9 depicts the synthesis of Formula F (COE2-3C-C4).
  • Figure 10 depicts the synthesis of Formula D (COE2-2B).
  • Figure 11 depicts the synthesis of Formula C (COE2-2py).
  • Figure 12 depicts the synthesis of Formula E (COE2-2hexyl).
  • Figures 13A-H depict the cytotoxicity of selected Formulae against Hep G2 cells.
  • Figures 14A-C depict the cytotoxicity of selected Formulae against NGH 3T3 cells.
  • Figures 15A-B depict the cytotoxicity of selected Formulae against J774 cells.
  • Figures 16A-C depict the cytotoxicity of selected Formulae tested by Eurofins
  • Figures 17A-C depict the cytotoxicity and antimicrobial profiles of selected
  • alkyl means a straight chain and/or branched hydrocarbon having from 1 to 20 (e.g., 1 to 10 or 1 to 4) carbon atoms, i.e., C1-C20 (including any integer number of carbon atoms between 1 and 20).
  • Alkyl moieties having from 1 to 4 carbons are referred to as“lower alkyl.”
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl.
  • alkenyl means a straight chain and/or branched hydrocarbon having from 2 to 20 (e.g., 2 to 10 or 2 to 6) carbon atoms, and including at least one carbon-carbon double bond.
  • alkenyl moieties include vinyl, allyl, 1- butenyl, 2-butenyl, isobutyl enyl, l-pentenyl, 2-pentenyl, 3 -methyl- l-butenyl, 2-methyl-2- butenyl, 2,3-dimethyl-2-butenyl, l-hexenyl, 2-hexenyl, 3-hexenyl, l-heptenyl, 2-heptenyl, 3- heptenyl, l-octenyl, 2-octenyl, 3-octenyl, l-nonenyl, 2-nonenyl, 3-nonenyl, l-decenyl, 2-decenyl and 3-decenyl.
  • alkynyl means a straight chain and/or branched having from 2 to 20 (e.g., 2 to 20 or 2 to 6) carbon atoms, and including at least one carbon-carbon triple bond.
  • alkynyl moieties include acetyl enyl, propynyl, 1- butynyl, 2-butynyl, l-pentynyl, 2-pentynyl, 3 -methyl- l-butynyl, 4-pentynyl, l-hexynyl, 2- hexynyl, 5-hexynyl, l-heptynyl, 2-heptynyl, 6-heptynyl, l-octynyl, 2-octynyl, 7-octynyl, 1- nonynyl, 2-nonynyl, 8-nonynyl, l-decynyl, 2-decynyl and 9-decynyl.
  • alkylene or“alkylene chain” refers to a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), and having from one to twenty carbon atoms, e.g., methylene, ethylene, propylene, «-butylene, ethenylene, propenylene, «-butenylene, propynylene, «-butynylene, and the like.
  • the alkylene chain is attached via a single or double bond.
  • arylene is used as understood by those skilled in the art, and refers to a divalent aryl group that is derived from an aryl group as provided herein, wherein two hydrogen as removed.
  • alkoxy means an -O-alkyl group.
  • alkoxy groups include, but are not limited to, -OCH3, -OCH2CH3, - 0(CH 2 ) 2 CH 3 , -0(CH 2 )3CH 3 , -0(CH 2 ) 4 CH3, and -0(CH 2 ) 5 CH3.
  • aryl means a monocyclic or multicyclic
  • aryl (e.g., bicyclic or tricyclic) ring system composed of carbon and hydrogen atoms, wherein the aryl has a fully delocalized pi-electron system throughout all the rings.
  • An aryl moiety may comprise multiple rings bound or fused together. Examples of aryl moieties include, but are not limited to, anthracenyl, azulenyl, naphthyl, phenanthrenyl, and phenyl.
  • arylalkyl or“aryl-alkyl” means an aryl moiety bound to an alkyl moiety.
  • halogen and“halo” encompass fluorine, chlorine, bromine, and iodine.
  • heteroalkyl refers to an alkyl moiety in which at least one of its carbon atoms has been replaced with a heteroatom (e.g., N, O or S).
  • heteroaryl means an aryl moiety wherein at least one of its carbon atoms has been replaced with a heteroatom (e.g., N, O or S).
  • heteroatom e.g., N, O or S.
  • examples include, but are not limited to, acridinyl, benzimidazolyl, benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoquinazolinyl, benzothiazolyl, benzoxazolyl, furyl, imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyridinium, pyrimidinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolinyl, te
  • heteroarylalkyl or “heteroaryl-alkyl” means a heteroaryl moiety bound to an alkyl moiety.
  • heterocycle refers to a non-aromatic monocyclic or polycyclic ring or ring system comprised of carbon, hydrogen and at least one heteroatom (e.g., N, O or S).
  • a heterocycle may comprise multiple (i.e., two or more) rings fused or bound together.
  • the fused heterocyclyls can be fused via two adjacent atoms.
  • the fused heterocyclyls can also be bridged heterocyclyls, wherein the rings are fused via non- adjacent atoms.
  • Heterocycles include heteroaryls.
  • Examples include, but are not limited to, benzo[l,3]dioxolyl, 2,3-dihydro-benzo[l,4]dioxinyl, cinnolinyl, furanyl, hydantoinyl, morphobnyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyrrolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl and valerolactamyl.
  • hydroxyalkyl refers to an alkyl that is substituted with 1 or more hydroxy groups.
  • hydroxyalkyl groups can have one of the following structures: -(CH2) I-4- OH and -(CH2) I -4-CH(OH)-(CH2) I -4-OH.
  • aminoalkyl refers to an alkyl that is substituted with 1 or more amino groups.
  • aminoalkyl groups can have one of the following structures: -(CH2)I -4 -NH2 and -(CH2)I-4-CH(NH2)-(CH2)I-4-NH2.
  • the p (pi) system of a molecule is used as understood by those skilled in the art.
  • the (pi) system of a molecule is formed by the interaction of unhybridized p atomic orbitals on atoms that have sp 2 - and sp-hybridization. The interaction that results in p bonding takes place between p orbitals that are adjacent by virtue of a s bond joining the atoms and takes the form of side-to-side overlap of p orbitals.
  • each center may independently be of R-configuration or S-configuration or a mixture thereof.
  • the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched or a stereoisomeric mixture.
  • each double bond may independently be E or Z a mixture thereof.
  • all tautomeric forms are also intended to be included.
  • valencies are to be filled with hydrogens or isotopes thereof, e.g., hydrogen- 1 (protium) and hydrogen-2 (deuterium).
  • each chemical element as represented in a compound structure may include any isotope of said element.
  • a hydrogen atom may be explicitly disclosed or understood to be present in the compound.
  • the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen- 1 (protium) and hydrogen-2 (deuterium).
  • reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
  • the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates and hydrates.
  • the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol or the like.
  • the compounds described herein exist in unsolvated form.
  • Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol or the like. Hydrates are formed when the solvent is water or alcoholates are formed when the solvent is alcohol.
  • the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
  • the term“pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases.
  • Suitable pharmaceutically acceptable base addition salts include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranibc, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandebc, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid.
  • inorganic and organic acids such as acetic, alginic, anthranibc, benzenesulfonic, benzoic, camphors
  • Non-toxic acids include hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids.
  • Examples of specific salts thus include hydrochloride and mesylate salts.
  • Others are well known in the art. See, e.g., Remington’s Pharmaceutical Sciences (18th ed., Mack Publishing, Easton Pa.: 1990) and Remington: The Science and Practice of Pharmacy (l9th ed., Mack Publishing, Easton Pa. : 1995).
  • the term“protecting group” or“protective group,” when used to refer to part of a molecule subjected to a chemical reaction, means a chemical moiety that is not reactive under the conditions of that chemical reaction, and which may be removed to provide a moiety that is reactive under those conditions.
  • Protecting groups are well known in the art. See, e.g., Greene, T. W. and Wuts, P. G. M., Protective Groups in Organic Synthesis (3 rd ed., John Wiley & Sons: 1999); Larock, R. C, Comprehensive Organic Transformations (2 nd ed., John Wiley & Sons: 1999).
  • the term“substituted,” when used to describe a chemical structure or moiety, refers to a derivative of that structure or moiety wherein one or more of its hydrogen atoms is substituted with a chemical moiety or functional group such as, but not limited to, alcohol, aldehyde, alkoxy, alkanoyloxy, alkoxy carbonyl, alkenyl, alkyl (e.g., methyl, ethyl, propyl, t-butyl), alkynyl, alkylcarbonyloxy (-OC(O)alkyl), amide (-C(O)NH-alkyl- or -NHC(O)alkyl), amidinyl (-C(NH)NHalkyl or -C(NR)NH 2 ), amine (primary, secondary and tertiary such as alkylamino, arylamino, arylalkylamino; quaternary tetralkylammoni
  • Substitutions are optionally functionalized with one or more functional groups of hydroxyl, thiol, thioether, ketone, aldehyde, ester, ether, amine, imine, amide, nitro, carboxylic acid, disulfide, carbonate, isocyanate, carbodiimide, carboalkoxy, peroxo, anhydride, carbamate, and halogen.
  • the term“comprising” or“comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It will be understood by those within the art that, in general, terms used herein are generally intended as“open” terms (e.g., the term“including” should be interpreted as“including but not limited to,” the term “having” should be interpreted as“having at least,” the term“includes” should be interpreted as “includes but is not limited to,” etc.).
  • compositions with an antimicrobial activity at a dosage range that is nontoxic to mammalian cells.
  • Conjugated oligoelectrolytes are a class of molecules that have been studied in bioelectrochemical systems, such as microbial fuel cells and electrobiosynthesis platforms. Twelve COEs with phenylenevinylene (PV) repeat units were examined with respect to their microbial membrane disrupting properties as a function of chemical structure. However, the toxicity toward mammalian cells has not been studied previously, which prevents the identification of COE candidates that are specifically promising for antimicrobial drug design.
  • Short COE molecules and their modifications are provided to increase their interactions with cells.
  • increasing the hydrophobic content enhances the interaction of the COE molecules with microbial cell walls and/or microbial membranes.
  • the disclosed COEs exhibit significant antimicrobial efficacy against both Gram-negative and Gram-positive bacteria relative to common antibiotics, while displaying minimal toxicity toward RAW264.7 murine macrophages, relative to all COE variations reported previously.
  • the COEs described herein, such as COE2-2hexyl show superior efficacy relative to conventional antibiotics.
  • Conjugated oligoelectrolytes are provided to intercalate into cell membranes.
  • the COEs have a general structure of Formula 1 :
  • p represents a pi conjugation structure, with exemplary structure as follows:
  • n 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • m is 0, 1, 2, 3 or 4 and in which Ri is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl
  • p and q are, independently, 1, 2, 3, 4 or 5 and in which R 2 and R 2’ are, independently, C 1 -C 20 alkynyl chain,— O— ,— S— ,— CO— ,— COO— , — OCO— ,— SO— ,— SO2— ,— N— or— NCO—
  • R3, Rr, R 4 and R 4’ are the same or different and constitute a straight-chain, branched or cyclic, substituted or unsubstituted Ci- C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl
  • R 6 and R 6 are the same or different pendant group, which could be cationic, include but not limited to ammonium, pyridinium and phosphonium, or anionic, such as -CO 2 , -SO 3 ; and one or more of the unsubstituted aromatic carbon atoms may be replaced by nitrogen, oxygen, and/or sulfur atoms.
  • the COEs can have a general structure of Formula 2:
  • n 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • m is 0, 1, 2, 3 or 4 and in which Ri is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl or aryl, optionally two or more Ri combine to form a cyclic or aromatic group
  • p and q are, independently, 1, 2, 3, 4 or 5 and in which R2 and R2’ are, independently, Ci- C20 alkynyl chain,— O— ,— S— ,— CO— ,— COO— ,— OCO— ,— SO— ,— S02— ,— N— or — NCO—
  • R3, Rr, R4 and R4 are the same or different and constitute a straight- chain, branched or cyclic, substituted or unsubstituted C1-C20 alkyl, C2-C
  • R 6 and R 6 are the same or different pendant group, which could be cationic, include but not limited to ammonium, pyridinium and phosphonium, or anionic, such as -CO2 , -S03 ;chemical bonds depicted with one solid line parallel to one dashed line encompass both single and double (e.g., aromatic) bonds, if valences permit; and one or more of the unsubstituted aromatic carbon atoms may be replaced by nitrogen, oxygen, and/or sulfur atoms.
  • the repeating core unit in the parenthesis with a subscript, n may be optionally replaced with
  • the COEs can have a structure of Formula 3,
  • n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • m is 0, 1, 2, 3 or 4 and in which Ri is, independently, an electron withdrawing group or an electron donating group, optionally two or more Ri combine to form a cyclic or aromatic group
  • p and q are, independently, 1, 2, 3, 4 or 5 and in which R 2 and R 3 are, independently,— X(R 4 ) wherein— X— represents a single bond,— O— , — S— ,—CO—,—COO—,—OCO—,—SO—,— S02— ,— N(Rs)— or— N(R 5 )CO—
  • R 4 and R5 are the same or different and constitute a straight- chain, branched or cyclic, substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl; chemical bonds depicted with one solid line
  • R 4 and R 5 is substituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl, where the substitution includes a cationic group.
  • the cationic group is a quaternary ammonium or a pyridinium cationic group, which is optionally further substituted with C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl.
  • the counter ions to the cationic group may be a charge compensating anion, including but not limited to halides (G, Br , Cl , or F ), organic anion, BIm 4 , B(ArF) 4 .
  • the counter ions to the anionic group could be alkaline metal, Na + , K + , Ca 2+ , or organic cation, tetralkyl ammoniums, pyridiums.
  • these COEs have a structural Formula 3-a:
  • the COEs have a structure of Formula 3 -a, wherein n is 0,
  • m can be 0. In other embodiments, m can be 1. In still other embodiments, m can be 2. In yet still other embodiments, m can be 3. In some embodiments, m can be 4. When m is 1 or 4 greater, each Ri can be independently a substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, alkoxy, amine, or thioether.
  • n can be 0. In other embodiments, n can be 1. In still other embodiments, n can be 2.
  • p can be 1, 2 or 3; and q can be 1, 2 or 3.
  • p and q can be each be 1.
  • p and q can be each be 2.
  • p and q can be each be 3.
  • R2 and R3 can be each— X(R4). In some embodiments, including those of the previous paragraph, R2 and R3 can be each— 0(R 4 ). When R2 and R3 are each— 0(R 4 ), then each R4 can be a substituted C1-C20 alkyl. For example, R2 and R3 are each — 0(R4), then each R4 can be a substituted C3-C10 alkyl; or R2 and R3 are each — 0(R 4 ), then each R4 can be a substituted C 4 -C 8 alkyl.
  • compositions having a general structure of Formula 3 -a have an oligophenylenevinylene p-conjugated structure.
  • the composition preferentially inhibits bacterial over mammalian cell growth, such that they are bactericidal yet safe to mammalian cells.
  • the COEs of Formula 3 -a have different numbers for p and q (each independently selected from 1, 2, 3, 4 and 5), and/or different chemical moieties for R2 and R3, each independently being— X(R 4 ), wherein— X— represents a single bond,— O— ,— S— , —CO—, —COO—,— OCO— , —SO—, — S0 2— , — N(Rs)— or— N(R 5 )CO— , and wherein R4 and R 5 are the same or different and constitute a substituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl or aryl, and the substitution is a quaternary ammonium or a pyridinium cationic group, wherein the quaternary ammonium or pyridinium is optionally substituted with a C1-C20 alkyl, C2-C20 alkeny
  • Ri is, independently, an electron withdrawing group or an electron donating group, optionally two or more Ri combine to form a cyclic or aromatic group
  • x and u represent the numbers of substitutions on the phenyl group and are, independently, 1, 2, 3, 4, or 5;
  • Re and R 7 are, independently, -0-, -S-, -C(O)-, -C(0)0- -OC(O)-, -S(O)-, -S(0) 2 _ , -N-, -NC(O)-, -C(0)N-;
  • y and v represent the numbers of substitutions on R 7 and R 6 , respectively, and are, independently, 1 for O and 1 or 2 for N;
  • Rx and R 9 are, independently, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl; N ⁇ each represents a quaternary ammonium
  • p can be aryl or heteroaryl.
  • p can be a phenyl, a monocyclic heteroaryl or a bicyclic heteroaryl.
  • p can be In some embodiments, p can be In some embodiments, p can be In some embodiments, p can be In some embodiments, p can be In some embodiments, n can be 1. In some embodiments, when n is 1, then p can be In other embodiments, n can be 3. In
  • n when n is 3, then p can be . In still other embodiments, n can be 5. In some embodiments when n is 5, then p can be
  • m can be 0. In other embodiments, m can be 1. In still other embodiments, m can be 2. In yet still other embodiments, m can be 3. In some embodiments, m can be 4. When m is 1 or 4 greater, each Ri can be independently a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, aryl, alkoxy, amine, or thioether.
  • phenyl rings shown in Formula 4 can be substituted multiple times.
  • x can be 2.
  • x can be 3.
  • u can be 2.
  • u can be 3.
  • the phenyl group can be substituted at the meta-positions and/or the para-positions.
  • Formula 4 can have the structure Further, when x and u are each 3 and each phenyl group is substituted at the meta- and para- positions, Formula 4 can have
  • Re and R 7 are, independently, O or N.
  • each R 7 can be O; and y and v can be each 1.
  • each R 7 can be N; and y and v can be each 2.
  • Formula 4 can have the structure:
  • Formula 4 can have the structure:
  • R 8 and R 9 can be each C 1 -C 20 alkyl. In some embodiments, R 8 and R 9 can be each C 2 -C 10 alkyl. In other embodiments, Rx and R 9 can be each C 3 -C 8 alkyl. In still other embodiments, Rx and R 9 can be each C 4 -C 6 alkyl.
  • each z can be 3. In some embodiments, each w can be 3.
  • each z and each w can be 3.
  • Rio and Rn are, independently, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl or aryl.
  • Rio can be C 1 -C 20 alkyl.
  • R 11 can be C 1 -C 20 alkyl.
  • Rio and R 11 can be C 1 -C 20 alkyl.
  • Rio and R 11 can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched or straight chained) or hexyl (branched or straight chained).
  • each z and each w can be 3; and each Rio and each Rn can be C 1 -C 20 alkyl such as those described herein.
  • each z and each w can be 3; and each Rio and each Rn can be Ci-C 6 alkyl.
  • each z and each w can be 3; and each Rio and each Rn can be methyl.
  • each z and each w can be 3; and each Rio and each Rn can be C2-C6 alkyl (for example, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched or straight chained) or hexyl (branched or straight chained)).
  • each Rio and each Rn can be C2-C6 alkyl (for example, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched or straight chained) or hexyl (branched or straight chained)).
  • each R l2 is independently -0-Ri4-N(R l5 )3 or -0-R l4 -R l7 ; each R13 is independently H or
  • R12; RM and R1 ⁇ 2 are independently C2-C10 alkyl; each R15 is independently H, C1-C10 alkyl,
  • R 15 is taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl;
  • R 17 is an unsubstituted or substituted N-linked pyridinyl, -
  • each Rix is independently C 2 -C 10 alkyl, hydroxyalkyl,
  • aminoalkyl O or -((CH 2 ) 2- 0) I-4 -CH 3 ; w is 0, 1 or 2; and the counter ions include G, Br , Cl , F , organic anion, BIm 4 or B(ArF) 4 .
  • N(Ri 5 ) 3 and R 17 ) can vary.
  • the alkyl can be 2 to 10 carbons in length.
  • R 12 is -0-R l4 -N(R l5 )3
  • the alkyl can be a C2-C10 alkyl.
  • R l4 can be -(CM?)?-.
  • Ru can be -(OT -
  • R l4 can be -(CH2) 4-
  • R l4 can be -(CTR) . ;-.
  • R l4 can be -(CFbje--.
  • R] 4 can be ---(Cl b.)?- -.
  • R J 4 can be -(CTbJs-.
  • RI 4 can be (O f .' b .
  • R l4 can be -(CIT J O -.
  • one or more of the hydrogens of the R 44 groups can be substituted with one or more -OH, -NH2, -SO3 , C1-C20 alkyl, or -N + (CH3)2R7a, wherein R7a can be C1-C20 alkyl.
  • each R12 can be independently -0-Ri4-N(Ri 5 )3.
  • the terminal group of N(Ri 5 ) 3 can be various substituents.
  • each R 15 can be the same. In other embodiments, each R 15 can be different. In some embodiments, each R 15 can be independently C1-C10 alkyl. As an example, each R15 can be methyl. As other examples, each R 15 can be C 2 -C 10 alkyl. In some embodiments, each R 15 can be C 2 -C 8 alkyl. In other embodiments, each R 15 can be C 4 -C 6 alkyl. In still other embodiments, each R 15 can be H.
  • two R 15 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl.
  • two R 15 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl; and the remaining R15 can be C1-C10 alkyl.
  • the monocyclic N-linked heterocyclyl can be 5-membered or a 6-membered monocyclic N-linked
  • heterocyclyl examples include:
  • the monocyclic N-linked heterocyclyl can be unsubstituted or substituted. When substituted, the non-hydrogen group can replace any hydrogen of the monocyclic N-linked heterocyclyl.
  • two R 15 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl described herein, and the remaining R 15 can be methyl.
  • two R 15 can be taken together with the nitrogen to which they are attached to form a bicyclic N-linked heterocyclyl; and the remaining R 15 can be C 1 -C 10 alkyl.
  • the bicyclic N-linked heterocyclyl can be a fused-bicyclic N-linked heterocyclyl, such as a bridged-bicyclic N-linked heterocyclyl.
  • the size of the bicyclic N-linked heterocyclyl can vary.
  • the bicyclic N-linked heterocyclyl can be a 7- or 8-membered bicyclic N-linked heterocyclyl.
  • bicyclic N-linked heterocyclyls include The bicyclic N-linked heterocyclyl, including those specific bicyclic N-linked heterocyclyls, can be unsubstituted or substituted. When substituted, the non-hydrogen group can replace any hydrogen of the monocyclic N-linked heterocyclyl.
  • one or more R15 groups can be hydroxyalkyl. As described herein, one or more hydroxy groups can be present on a hydroxyalkyl. In some embodiments, the hydroxyalkyl 42 OH can be -(CH2) I-4- OH. In other embodiments, the hydroxyalkyl can be OH wherein al and a2 can be independently 1 or 2. In other embodiments, one or more R15 groups can be aminoalkyl, such as a -(03 ⁇ 4)i- 4- NH 2 . In still other embodiments, one or more R15 groups
  • one or more R15 groups can be -
  • R15 group is -((O3 ⁇ 4) 2- 0)i- 4 -O3 ⁇ 4, one or more R15
  • one or more R15 groups can be hydroxyalkyl, aminoalkyl,
  • R15 groups can be C1-C10 alkyl.
  • one R15 group can be hydroxyalkyl,
  • two R15 groups can be independently C1-C10 alkyl. In other embodiments, two R15 groups can be hydroxyalkyl, O
  • R 15 group can be C 1 -C 10 alkyl.
  • two R 15 groups can be hydroxyalkyl, aminoalkyl, O ' or
  • R 15 group can be C 4 -C 6 alkyl. In some embodiments, two R 15
  • R 15 group can be Ci-C 4 alkyl.
  • each R12 can be independently -G ⁇
  • Ri 4 can be a C2-C10 alkyl as described in paragraph [0083]
  • Rr ? can be an unsubstituted N-linked pyridinyl. In other embodiments, Rr ? can be a substituted N-linked pyridinyl.
  • N-linked pyridinyl When the N-linked pyridinyl is substituted, the pyridinyl can be substituted one or more times with a substituent independently selected from an electron-donating group and electron-withdrawing group.
  • N-linked pyridinyl can be substituted with a substituent selected from a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, aryl, alkoxy, amine, or thioether.
  • R l7 can be -(C 2 -C 3 alkyl)N(Ri x)?.
  • R l7 can be - (CH 2 )2N(Rl8)3 or -(CH 2 )3N(Rl8)3.
  • each Ris can be the same. In other embodiments, each ig can be different. In some embodiments, each Rig can be independently C 1 -C 10 alkyl. In some embodiments, each Rig can be methyl. In other embodiments, each Rig can be C 2 -C 10 alkyl. In some embodiments, each Rig can be C 2 -C 8 alkyl. In other embodiments, each Rig can be C 4 -C 6 alkyl.
  • two Ris can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl.
  • two R ix can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl; and the remaining Rix can be Ci-Cio alkyl.
  • the monocyclic N-linked heterocyclyl can be 5-membered or a 6-membered monocyclic N-linked heterocyclyl, such as those described herein.
  • the monocyclic N-linked heterocyclyl can be unsubstituted or substituted.
  • two R ix can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl described herein, and the remaining Rix can be methyl.
  • two R ix can be taken together with the nitrogen to which they are attached to form a bicyclic N-linked heterocyclyl; and the remaining R ix can be C1-C10 alkyl.
  • the bicyclic N-linked heterocyclyl can be a fused-bicyclic N-linked heterocyclyl, such as a bridged-bicyclic N-linked heterocyclyl.
  • the size of the bicyclic N-linked heterocyclyl can vary.
  • the bicyclic N-linked heterocyclyl can be a 7- or 8-membered bicyclic N-linked heterocyclyl.
  • the bicyclic N-linked heterocyclyl can be unsubstituted or substituted.
  • the non-hydrogen group can replace any hydrogen of the monocyclic and/or bicyclic N-linked heterocyclyls.
  • one or more R ix groups can be hydroxyalkyl. As described herein, one or more hydroxy groups can be present on a hydroxyalkyl. In some embodiments,
  • the hydroxyalkyl can be -(CH 2 ) I-4- OH or OH , wherein bl and b2 can be independently 1 or 2.
  • one or more R ix groups can be aminoalkyl, such as a -(CH2) I-4 -NH2.
  • one or more Rix groups can be O
  • one or more Rix groups can be -((CH 2 ) 2-
  • one or more Ris groups can be hydroxyalkyl, aminoalkyl,
  • one or more Rix groups can be
  • Rix groups can be Ci-Cio alkyl.
  • one Rix group can be hydroxyalkyl,
  • two Rix groups can be independently Ci-Cio alkyl. In other embodiments, two Rix groups can be hydroxyalkyl,
  • Rix group can be Ci-Cio alkyl.
  • two Rix groups can be hydroxyalkyl, aminoalkyl, O or
  • Ris group can be C4-C6 alkyl. In some embodiments, two Rix
  • groups can be hydroxyalkyl, aminoalkyl, O or -(( ⁇ 3 ⁇ 4) 2- 0)i- 4 -O3 ⁇ 4; and one
  • R15 group can be C1-C4 alkyl.
  • w can be 0, 1 or 2. In some embodiments, when w is 0, the
  • compound of Formula 5 can have the structure: .
  • w 1, the compound of Formula 5 can have the structure:
  • the compound of Formula 5 when w is 2, can have the structure:
  • R l4 when each R l2 and Rr, is H, then R l4 is not a Cs or Ce alkyl.
  • R17 when R12 is O-R14-R17, then R17 cannot be -NH-
  • R 15 cannot be methyl.
  • R12 when R is O-R14-R17, then R17 cannot be an unsubstituted or substituted N- linked pyridinyl.
  • each R 15 cannot be methyl.
  • R cannot be C 3 alkyl.
  • R I4 cannot be C 6 alkyl.
  • Ri cannot be halide, such as F.
  • Ri cannot be alkoxy.
  • Ri cannot be cyano.
  • the COEs have a structural Formula 6:
  • R 24 is independently C 2 -C 10 alkyl; each R 23 is independently H, C 1 -C 10 alkyl, hydroxyalkyl,
  • R25 is an unsubstituted or substituted N-linked pyridinyl, -(C2-3 alkyl)N(R26)3 each R26 is independently C2-C10 alkyl, hydroxyalkyl, aminoalkyl, r -((CH 2 ) 2- 0) I-4 -CH 3 ; x is 0, 1 or 2; and the counter ions include G, Br , Cl , F , organic anion, BIn or B(ArF) 4 .
  • each of R 19 , R 20 and R 2l can be independently -0-R 22 -
  • R22 can be C2-C10 alkyl. In some embodiments, R22 can be - (01 2 ) 2- . In other embodiments, R 22 can be -(01 2 ) 3- . In still other embodiments, R 22 can be - (Ci ! ⁇ ).; . In yet still other embodiments, R22 can be (CH 2 )5 . In some embodiments, R22 can be (O f'),, . In other embodiments, R 22 can be -(CHz) ?- In still other embodiments, R 22 can be - (0 1 ⁇ )H In yet still embodiments, R 22 can be -(03 ⁇ 4) 9-- .
  • R 22 can be - (CH2) l0- .
  • one or more of the hydrogens of the R22 groups can be substituted with one or more -OH, -NH 2 , -SO3 -, C1-C20 alkyl, or -N + (CH3)2R7 b , wherein ⁇ can be C1-C20 alkyl.
  • each R 23 can be the same. In other embodiments, each R 23 can be different. In some embodiments, each R 23 can be independently C 1 -C 10 alkyl. As an example, each R 23 can be methyl. As other examples, each R 23 can be C 2 -C 10 alkyl. In some embodiments, each R 23 can be C 2 -C 8 alkyl. In other embodiments, each R 23 can be C 4 -C 6 alkyl. In still other embodiments, each R 23 can be H.
  • two R 23 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl. Examples of monocyclic and bicyclic heterocyclyls are described herein, including those described with respect to R15. In some embodiments, two R23 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl; and the remaining R 23 can be C 1 -C 10 alkyl.
  • the monocyclic N-linked heterocyclyl can be 5-membered or a 6-membered monocyclic N-linked heterocyclyl.
  • two R 23 can be taken together with the nitrogen to which they are attached to form a bicyclic N-linked heterocyclyl; and the remaining R 23 can be C 1 -C 10 alkyl.
  • the bicyclic N-linked heterocyclyl can be a fused-bicyclic N-linked heterocyclyl, such as a bridged-bicyclic N-linked heterocyclyl.
  • the size of the bicyclic N-linked heterocyclyl can vary.
  • the bicyclic N-linked heterocyclyl can be a 7- or 8-membered bicyclic N-linked heterocyclyl.
  • two R 23 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N- linked heterocyclyl described herein, and the remaining R 23 can be methyl.
  • linked heterocyclyls include: and The monocyclic N-linked heterocyclyl and bicyclic N-linked heterocyclyls can be unsubstituted or substituted. When substituted, the non-hydrogen group can replace any hydrogen of the monocyclic and/or bicyclic N-linked heterocyclyls.
  • R 23 group can be present and include hydroxyalkyl, aminoalkyl,
  • one or more R 23 groups can be hydroxyalkyl. As described herein, one or more hydroxy groups can be present on a hydroxyalkyl. In some embodiments, the hydroxyalkyl can be -(O3 ⁇ 4)i- 4- 0H. In other words,
  • the hydroxyalkyl can be OH , wherein al and a2 can be independently 1 or 2.
  • one or more R 23 groups can be aminoalkyl, such as a — (CH2) 1 - 4— NFI 2 .
  • one or more R 23 groups can be
  • one or more R 23 groups can be -((C h ⁇ - 0)I-4-CH3.
  • an R23 group is -((O3 ⁇ 4)2-0)i-4-O3 ⁇ 4, one or more R23 groups can
  • one or more R23 groups can be hydroxyalkyl, aminoalkyl,
  • R23 groups can be C1-C10 alkyl.
  • one R23 group can be hydroxyalkyl, aminoalkyl, O or
  • R23 groups can be independently C1-C10 alkyl.
  • two R 23 groups can be hydroxyalkyl, aminoalkyl, O or -((O ⁇ 2)2-0)i -4 -O3 ⁇ 4; and one R 23 group can be C 1 -C 10 alkyl. In some embodiments, two R 23
  • groups can be hydroxyalkyl, aminoalkyl, O or -((O ⁇ 2)2-0)i-4-O3 ⁇ 4; and one
  • R 23 group can be C 4 -C 6 alkyl. In some embodiments, two R 23 groups can be hydroxyalkyl,
  • R 23 group can be C 1 -C 4 alkyl.
  • each of R19, R20 and R21 can be independently -O-R24-R25.
  • R 24 can be a C 2 -C 10 alkyl as described in paragraph [0083] with respect to R I4 .
  • R 24 can be - ⁇ CH 2 )3-, -(CH 2 ) 4- , (O I Y . ⁇ ( ⁇ 2 ) ⁇ , . (Cl I ⁇ )- . (O l ⁇ ) * . -(CH 2 )9- or (Cl 1 ) 1 : i .
  • one or more of the hydrogens of the R 24 groups can be substituted with one or more -OH, -NH2, -SO3 -, C1-C20 alkyl, or -N + (CH3)2R7c, wherein R 7c can be C1-C20 alkyl.
  • R 25 can be an unsubstituted N-linked pyridinyl. In other embodiments, R 25 can be a substituted N-linked pyridinyl. A variety of substituents can be present on a substituted N-linked pyridinyl, and include a substituent independently selected from an electron-donating group and electron-withdrawing group. In some embodiments, N- linked pyridinyl can be substituted with a substituent selected from a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, aryl, alkoxy, amine, or thioether.
  • the number of substituents present on a substituted N-linked pyridinyl can also vary.
  • the substituted N-linked pyridinyl can be substituted 1, 2, 3, or 4 times.
  • each of R19, R20 and R21 can be -(C2-C3 alkyl)N(R26)3.
  • each of R19, R20 and R?.i can be - (CH 2 )2N(R 2 6)3 or -(CH 2 )3N(R 2 6)3.
  • each R 26 group can vary as described herein. In some embodiments, each R 26 can be the same. In other embodiments, each R 26 can be different. In some embodiments, each R 26 can be independently C 1 -C 10 alkyl. In some embodiments, each R 26 can be methyl. In other embodiments, each R 26 can be C2-C10 alkyl. In some embodiments, each R3 ⁇ 4 can be C 2 -C 8 alkyl. In other embodiments, each R 26 can be C 4 -C 6 alkyl.
  • x can be 0, 1 or 2. In some embodiments, when x is 0, the
  • compound of Formula 6 can have the structure: .
  • x 1, the compound of Formula 6 can have the structure:
  • the compound of Formula 6 can have the structure:
  • R 24 when R 22 is C 3 alkyl, then R 24 cannot be methyl. In some embodiments, when one or more of R 19 , R 2 o and R 2 ⁇ is -()-R 24 -R 2 5, then R 25 cannot be an unsubstituted or substituted N-linked pyridinyl. In some embodiments, each R 24 cannot be methyl. In some embodiments, including those of this paragraph, R 22 cannot be C 3 alkyl. In some embodiments, including those of this paragraph, R 22 cannot be G, alkyl. In some embodiments, including those of this paragraph, R 24 cannot be C3 alkyl. In some embodiments, including those of this paragraph, R 24 cannot be G, alkyl. [0110] In other embodiments, the COEs have a structural Formula 7:
  • R27 and R28 are independently -N-(R29)-N(R3o)3;
  • R29 is C2-C10 alkyl;
  • each R30 is independently H, C 1 -C 10 alkyl, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, aryl, hydroxyalkyl,
  • R 29 can be a C 2 -C 10 alkyl as described in paragraph [0083] with respect to R M .
  • Various R 30 groups can be present on a COE of Formula 7.
  • each R 30 can be the same. In other embodiments, each R 30 can be different.
  • each R 30 can be independently C 1 -C 10 alkyl. In some embodiments, each R 30 can be methyl. In other embodiments, each R 30 can be C 2 -C 10 alkyl. In some embodiments, each R 30 can be C 2 -C 8 alkyl. In other embodiments, each R 30 can be C 4 -C 6 alkyl. In some embodiments, each R 30 can be H.
  • R 30 can be C 2 -C 20 alkenyl. In some embodiments, R 30 can be C 2 -C 10 alkenyl. In some embodiments, R 30 can be C 4 -C 6 alkenyl. In other embodiments, R 30 can be C 2 -C 20 alkynyl, including, but not limited to, C 2 -C 10 alkynyl or C 4 -C 6 alkynyl. In still other embodiments, R 30 can be aryl, such as phenyl.
  • two R 30 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl. Examples of monocyclic and bicyclic heterocyclyls are described herein. In some embodiments, two R 30 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl; and the remaining R 30 can be C 1 -C 10 alkyl.
  • the monocyclic N-linked heterocyclyl can be 5-membered or a 6-membered monocyclic N-linked heterocyclyl.
  • two R30 can be taken together with the nitrogen to which they are attached to form a bicyclic N-linked heterocyclyl; and the remaining R 30 can be C 1 -C 10 alkyl.
  • the bicyclic N-linked heterocyclyl can be a fused-bicyclic N-linked heterocyclyl, such as a bridged- bicyclic N-linked heterocyclyl.
  • the size of the bicyclic N-linked heterocyclyl can vary.
  • the bicyclic N-linked heterocyclyl can be a 7- or 8-membered bicyclic N-linked heterocyclyl.
  • two R 30 can be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl or a bicyclic N-linked heterocyclyl described herein, and the remaining R 30 can be methyl.
  • N-linked heterocyclyls N-linked heterocyclyls
  • the monocyclic N-linked heterocyclyl and bicyclic N-linked heterocyclyls can be unsubstituted or substituted. When substituted, the non-hydrogen group can replace any hydrogen of the monocyclic and/or bicyclic N-linked heterocyclyls.
  • R30 group can be present and include hydroxyalkyl, aminoalkyl,
  • one or more R 30 groups can be hydroxyalkyl. As described herein, one or more hydroxy groups can be present on a hydroxyalkyl. In some embodiments, the hydroxyalkyl can be -(CH 2 ) I -4-OH. In other words,
  • the hydroxyalkyl can be OH , wherein al and a2 can be independently 1 or 2.
  • one or more R 30 groups can be aminoalkyl, such as
  • one or more R 30 groups can be .
  • one or more R 30 groups can be -((dis 0)i -4 -O3 ⁇ 4.
  • one or more R 23 groups can be -((dis 0)i -4 -O3 ⁇ 4.
  • one or more R 30 groups can be hydroxyalkyl, aminoalkyl,
  • R 30 groups can be C 1 -C 10 alkyl.
  • one R 30 group can be hydroxyalkyl, aminoalkyl, O or
  • R 23 groups can be independently C 1 -C 10 alkyl.
  • two R 23 groups can be hydroxyalkyl, aminoalkyl, O or
  • R 30 group can be C 1 -C 10 alkyl. In some embodiments, two R 23
  • R 30 group can be C 4 -C 6 alkyl. In some embodiments, two R 30 groups can be hydroxyalkyl,
  • R 30 group can be C 1 -C 4 alkyl.
  • y can be 1. In other embodiments, y can be 2.
  • R 29 cannot be Ce alkyl. In some embodiments, each R 30 cannot be methyl. In some embodiments, two R 30 cannot be taken together with the nitrogen to which they are attached to form a monocyclic N-linked heterocyclyl, such as morpholinyl. In some embodiments, y cannot be 1. In other embodiments, y cannot be 2. In some embodiments, including those of this paragraph, R 29 cannot be C 3 alkyl. In some embodiments, including those of this paragraph, R29 cannot be C 6 alkyl. In some embodiments, a COE of Formula 7 cannot be Formula VV. In some embodiments, a compound described herein cannot be a compound of Formula 7.
  • P is a P pi conjugated system wherein n is the number of conjugated centers and n
  • k is the number of electrons in the pi conjugated system
  • n 3-40;
  • k 3-40;
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C1-C20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered fused or bridged heterocycle;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH2, -S(0)20H, C1-C20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl;
  • a 0-5;
  • b is 1-5;
  • d 1-2.
  • a can be 0 and b can be 1-5. In another embodiment, a can be 1-5 and b can be 1-5.
  • P can be a pi conjugated system comprising p r , wherein p is a repeating pi conjugation structure and p is 0-10. In some embodiments, p can be 0-5. In another embodiment, p can be 0, 1, 2, or 3. [0122] In some embodiments, a compound is provided having the structure of Formula
  • p is a repeating pi conjugation structure
  • p 0-10
  • ring A and ring A’ are each, independently, optionally substituted aryl or optionally substituted heteroaryl;
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)- -C(0)0-, -OC(O)-, -S(O)-, -S(0) 2- , -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 5a and R 5b are at each occurrence, independently, C2-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl,
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH2, -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • p 0-10
  • ring A and ring A’ are each, independently, optionally substituted aryl or optionally substituted heteroaryl;
  • ring B is aryl or heteroaryl;
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH 3 ) 2 R 7 , wherein R 7 is C 1 -C 20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d is 1-2.
  • p 0-10
  • ring A and ring A’ are each, independently, optionally substituted aryl or optionally substituted heteroaryl;
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C1-C20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 5a and R 5b are at each occurrence, independently, C 2 -C 20 alkyl, C 2 -C 20 alkenyl, C2-C20 alkynyl, aryl, or at least one R 3a , and an adjacent R 4a , at each occurrence, or at least one R 3b and an adjacent R 4b , at each occurrence, together with the N to which they are attached, form a 5-8 membered monocyclic heterocycle;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • p 0-10
  • ring A and ring A’ are each, independently, optionally substituted aryl or optionally substituted heteroaryl;
  • ring B is aryl or heteroaryl
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3:l , R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH 3 ) 2 R 7 , wherein R 7 is C 1 -C 20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d is 1-2.
  • p is a repeating pi conjugation structure
  • p 0-10
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group;
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3:l , R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH 3 ) 2 R 7 , wherein R 7 is C 1 -C 20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(O)-, -C(0)0-, -OC(O)-, -S(O)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3a ’, R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • X and X’ are, independently, and at each occurrence, -0-, -S-, -C(0)-, -C(0)0-, -0C(0)-, -S(0)-, -S(0)2-, -N-, -NC(O)-, -C(0)N-, or a bond;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle;
  • R 3:l , R 3b , R 4a , R 4b , R 5a , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH 3 ) 2 R 7 , wherein R 7 is C 1 -C 20 alkyl;
  • a 1-5;
  • b is 1-5;
  • d 1-2.
  • a compound is provided wherein a and b are each 2 and having the structure of Formula (IV):
  • p is a repeating pi conjugation structure
  • p 0-10
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group;
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, or aryl;
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • c at each occurrence can be 2; d at each occurrence can be
  • p is a repeating pi conjugation structure
  • p 0-10
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , p 4a j ⁇ 4b anc j j ⁇ 4b are at eac ] 1 occurre nce, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH2, -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • p 0-10
  • ring B is aryl or heteroaryl
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • p 0-10
  • ring B is aryl or heteroaryl
  • n 0-12
  • R 1 is, independently, an electron withdrawing group, halide, or a substituted or unsubstituted C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , p 4a j ⁇ 4b anc j j ⁇ 4b are at eac ] 1 occurre nce, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a’ , R 3b , R 3b’ , R 4a , R 4a’ , R 4b , R 4b’ , R 5a , R 5a’ , R 5b ’, or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is C1-C20 alkyl.
  • ring B can be:
  • a compound wherein p is 0 and having the structure of Formula (IV-B-l):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C1-C20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b' are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , p 4a ' ⁇ j ⁇ 4b ⁇ anc j j ⁇ 4b ’ are at eac ] 1 occurre nce, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH2, -S(0)20H, C1-C20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • a compound wherein p is 1 and having the structure of Formula (IV-B-2):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b' are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a' , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH2, -S(0)20H, C1-C20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • a compound wherein p is 2 and having the structure of Formula (IV-B-3):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a' , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • a compound wherein p is 0 and having the structure of Formula (V-B-l):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , R 4a' , R 4b , and R 4b are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • a compound wherein p is 1 and having the structure of Formula (V-B-2):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b' are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 4a , p 4a ' ⁇ j ⁇ 4b ⁇ anc j j ⁇ 4b ’ are at eac ] 1 occurre nce, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl; and
  • R 3a and R 4a and R 5a , or R 3b , R 4b , and R 5b , or R 3a , R 4a' and R 5a , or R 3b' , R 4b' , and R 5b independently, together with the atoms to which they are attached, form an 8-14 membered bicyclic heterocycle; wherein R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C 1 -C 20 alkyl, or -N + (CH3)2R 7 , wherein R 7 is C1-C20 alkyl.
  • a compound wherein p is 2 and having the structure of Formula (V-B-3):
  • N ⁇ represents an ammonium, quaternary ammonium, imidazolium, or pyrrolidinium cationic group
  • R 2a and R 2b are, independently, and at each occurrence, C 1 -C 20 alkyl ene, arylene, or a bond;
  • R 3a , R 3a , R 3b , and R 3b' are at each occurrence, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • eac ] 1 occurre nce, independently, H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, or aryl;
  • R 3a ⁇ , R 3a' , R 3b , R 3b' , R 4a , R 4a' , R 4b , R 4b' , R 5a , R 5a' , R 5bl , or R 5b are each, independently, optionally substituted with one or more -OH, -NH 2 , -S(0) 2 0H, C1-C20 alkyl, or -N + (CH3) 2 R 7 , wherein R 7 is Ci-C 2 o alkyl.
  • R 5a and R 5b can be at each occurrence, independently,
  • R 5a and R 513 can be at each occurrence, independently, -(CH 2 CH 2 0) Z R 7 where z is 1-6, wherein R 7 can be Ci-C 2 o alkyl.
  • R 3a and R 4a , and R 3b and R 4b independently, together with the N to which they are independently attached, can form a 5-8 membered monocyclic heterocycle.
  • R 3a and an adjacent R 4a and R 5a at each occurrence, independently, or one R 3b and an adjacent R 4b and R 5b , at each occurrence, independently, together with the atoms to which they are attached, can form an 8-14 membered bicyclic heterocycle.
  • Exemplary COEs have a structure of any of Formulae A-H and J-XX:
  • the COEs have a structure of Formulae TT, UU, W or
  • the COEs in the composition and/or methods described herein are not, or do not include, one that has a structure of Formula A, Formula O, Formula ETU or Formula VV.
  • Some advantages of the COEs described herein compared to known COEs include how the molecular structure balances water solubility and efficacy.
  • increasing the hydrophobic components of the COE has been shown to increase efficacy.
  • COEs that have hexyl or cyclic groups (such as pyridinyl and piperidinyl) in place of the methyl groups attached to the quaternary nitrogens can have increased cell affinity and/or efficacy.
  • varying the hydrophobic components of the COEs described herein can reduce cytotoxicity.
  • the backbone of a compound described herein includes the phenyl groups and p moiety(ies).
  • one or more of the COEs have a high affinity towards cell membranes, especially bacterial cell membranes.
  • at least 50%, 60% or 70% of the COEs are taken up by or adsorbed to cells following incubation for 30 minutes, 1 hour, 1.5 hour, 2 hours or longer, given that the COEs are not at a concentration that oversaturates the cell culture medium or cells.
  • the one or more COEs having a high affinity towards cells are also readily soluble in water or an aqueous medium.
  • the solubility of the COEs is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 500, or 1,000 pg/mL in water.
  • the one or more COEs are active against Gram-negative bacteria. In some embodiments, the one or more COEs are active against Gram-positive bacteria. In some embodiments, the one or more COEs are active against both Gram-negative bacteria and Gram-positive bacteria. In various embodiments, one or more of the COEs have activity against one or more bacteria, such as Salmonella enterica Typhimurium (ST) (ATCC 14028); E.
  • ST Salmonella enterica Typhimurium
  • EC coli
  • PA Pseudomonas aeruginosa
  • KPN Klebsiella pneumoniae
  • MRSA methicillm-resistant S. aureus
  • MSSA methicillm-sensitive S. aureus
  • one or more of the COEs have a minimum inhibitory concentration (MIC) of less than 10, 20, 30, 40, 50, 60, or 70 mg/mL towards Gram-negative bacteria such as Salmonella enterica Typhimurium ATCC 14028; E.
  • MIC minimum inhibitory concentration
  • the one or more COEs having a low MIC towards Gram-negative bacteria also have a low MIC towards Gram-positive bacteria such as methicillin-resistant S. aureus (MRSA) USA300, MT3302, MT3315, ATCC 33591, and ATCC BAA-1717; methicillm-sensitive S. aureus (MSSA) Newman and MT3305; Streptococcus pneumoniae D39 and Daw 1 ; Enterococcus faecium (VRE) 1674620; Staphylococcus epidermidis ATCC 148990.
  • MRSA methicillin-resistant S. aureus
  • MSSA methicillm-sensitive S. aureus
  • the one or more COEs are active against Gram-negative bacteria and/or Gram-positive bacteria, and are non-toxic to mammalian cells.
  • the one or more COEs having a low MIC towards both Gram-negative and Gram positive bacteria are also non-toxic to mammalian cells.
  • a COE at a concentration above its MIC towards a bacterial strain results in greater than 50%, 60%, 70%, 80%, 90%, 95% or higher viable cells upon incubation with a mammalian cell type.
  • the COE compounds are stable, and COEs can be stored in a solid or solution form for years. No decomposition is observed by detecting using NMR or mass spectrometry. In most embodiments, they are readily synthesized in a large scale.
  • Structural features such as the length of the PV backbone and the presence of either a trimethylammonium or a pyridinium cationic pendant group appears to generally affect the antimicrobial activity of the compounds.
  • optical characteristics and interactions with cell membranes are determined by using LTV- Vis absorption and photoluminescence spectroscopies, and confocal microscopy. Toxicity tests on representative Gram-positive ⁇ Enterococcus faecalis ) and Gram-negative ⁇ Escherichia coli) bacteria revealed generally greater toxicity to E. faecalis than to E. coli and may indicate that shorter molecules have better antimicrobial activity.
  • an increased antimicrobial potency is observed in three-ring COEs appended with pyridinium ionic groups but not with COEs with four or five PV repeat units.
  • a COE with only two PV repeat units may not associate with cells to the same degree as its longer homologs (i.e., DSBN and DSSN).
  • the present application provides a pharmaceutical composition for treatment of bacterial infection in a mammalian subject.
  • the pharmaceutical composition includes one, two, three, four, or more compounds as represented by any of Formulae 1-7 (including Formula 3-a) and A-H and J-XX, and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition can include a compound of Formula E and a pharmaceutically acceptable excipient or carrier.
  • the pharmaceutical composition includes a compound of Formula E in combination with one or more other compounds as represented by any of Formulae A-D and F-XX, with a pharmaceutically acceptable excipient or carrier.
  • compositions according to the present application can contain any pharmaceutically acceptable excipient.
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.
  • excipients include but are not limited to starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, wetting agents, emulsifiers, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, antioxidants, plasticizers, gelling agents, thickeners, hardeners, setting agents, suspending agents, surfactants, humectants, carriers, stabilizers, and combinations thereof.
  • the pharmaceutical compositions according to the present application may be formulated for delivery via any route of administration.
  • “Route of administration” may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, oral, transmucosal, transdermal, parenteral or enteral.
  • “Parenteral” refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal.
  • the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.
  • the pharmaceutical compositions can be in the form of tablets, gel capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or lipid vesicles or polymer vesicles allowing controlled release.
  • the compositions are administered by oral consumption or by injection. Methods for these administrations are known to one skilled in the art.
  • compositions according to the present application can contain any pharmaceutically acceptable carrier.
  • “Pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof.
  • Each component of the carrier must be“pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
  • Another drug delivery system is sustained released or increased circulatory half-life vehicles such as the liposome.
  • Methods of preparing liposome delivery systems are discussed in Gabizon et al, Cancer Research (1982) 42:4734; Cafiso, Biochem Biophys Acta (1981) 649: 129; and Szoka, Ann Rev Biophys Eng (1980) 9:467.
  • Other drug delivery systems are known in the art and are described in, e.g., Poznansky et al, DRUG DELIVERY SYSTEMS (R. L. Juliano, ed., Oxford, N.Y. 1980), pp. 253-315; M. L. Poznansky, Pharm Revs (1984) 36:277.
  • compositions according to the present application can also be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water.
  • Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non- aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the liquid pharmaceutical composition may be lyophilized to prevent degradation and to preserve sterility.
  • Methods for lyophilizing liquid compositions are known to those of ordinary skill in the art.
  • the composition may be reconstituted with a sterile diluent (Ringer's solution, distilled water, or sterile saline, for example) which may include additional ingredients.
  • a sterile diluent Finger's solution, distilled water, or sterile saline, for example
  • the composition is administered to subjects using those methods that are known to those skilled in the art.
  • the pharmaceutical compositions according to the present application may be delivered in a therapeutically effective amount.
  • the precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration.
  • Formula 7, Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt of any of the foregoing can be synthesized using standard synthetic techniques known to those skilled in the art, wherein Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt of any of the foregoing, are as provided in the section entitled“Further Formulae.”
  • compounds of the present disclosure can be synthesized using appropriately modified synthetic procedures set forth in the general synthetic schemes detailed below and in the examples.
  • reaction may be carried out in any suitable solvent, or other reagents to perform the transformation(s) necessary.
  • suitable solvents are protic or aprotic solvents which are substantially non reactive with the reactants, the intermediates or products at the temperatures at which the reactions are carried out (i.e., temperatures which may range from the freezing to boiling temperatures).
  • a given reaction may be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular work-up following the reaction may be employed.
  • starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)).
  • B5 Two molecules of aldehyde B3 are reacted with B4 under appropriate Horner-Emmons-Wadsworth conditions (e.g. NaOtBu, THF) to provide B5.
  • B5 is similarly converted to a target compound by the same iodination/amination sequence.
  • Such functional groups include, but are not limited to, hydroxy, amino, mercapto and carboxylic acid.
  • Suitable protecting groups for hydroxy include, but are not limited to, trialkylsilyl or diarylalkylsilyl (for example, t- butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like).
  • Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl ("Boc"), benzyloxycarbonyl, and the like.
  • Protecting groups are optionally added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein.
  • protecting groups are described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.
  • the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
  • a method of treating, reducing the severity of and/or slowing the progression of a bacterial infection in a mammalian subject including administering an effective amount of one, two, three, four, or more COEs of any of Formulae 1-7 (including Formula 3-a) and A-H and J-XX to a mammalian subject.
  • the effective amount of the COEs are non-toxic to the normal tissue or cells of the mammalian subject.
  • the mammalian subject is a human.
  • the method of treating, reducing the severity of and/or slowing the progression of a bacterial infection in a mammalian subject has a specific efficacy towards Gram-negative, Gram-positive, or both, yet maintains the viability of normal mammalian cells of at least 70%, 80%, 90%, 95% or greater.
  • the effective amounts of the COE(s) in the methods and/or compositions described herein may be in the range of about 0.001-0.01 mg/kg/day, 0.01-0.05 mg/kg/day, 0.05-0.1 mg/kg/day, 0.1-0.2 mg/kg/day, 0.2-0.3 mg/kg/day, 0.3-0.4 mg/kg/day, 0.4- 0.5 mg/kg/day, 0.5-1 mg/kg/day, 1-5 mg/kg/day, 5-10 mg/kg/day, 10-20 mg/kg/day, 20-30 mg/kg/day, 30-40 mg/kg/day, 40-50 mg/kg/day, 50-60 mg/kg/day, 60-70 mg/kg/day, 70-80 mg/kg/day, 80-90 mg/kg/day, 90-100 mg/kg/day, 100-200 mg/kg/day, 200-300 mg/kg/day, 300- 400 mg/kg/day, 400-500 mg/kg/day, 500-600 mg/kg/day,
  • the effective amounts of the COE(s) in the methods and/or compositions descried herein may be in the range of about 1-10 mg/kg/week, 10-30 mg/kg/week, 30-50 mg/kg/week, 50-100 mg/kg/week, 100-200 mg/kg/week, 200-300 mg/kg/week, 300-400 mg/kg/week, 400-500 mg/kg/week, 500-600 mg/kg/week, 600-700 mg/kg/week, 700-800 mg/kg/week, 800-900 mg/kg/week, 900-1000 mg/kg/week, 1000-1100 mg/kg/week, 1100-1200 mg/kg/week, 1200-1300 mg/kg/week, 1300-1400 mg/kg/week, 1400-1500 mg/kg/week, 1500- 1600 mg/kg/week, 1600-1700 mg/kg/week, 1700-1800 mg/kg/week, 1800-1900 mg/kg/week or 1900-2000 mg/kg/week.
  • the methods described herein treats, reduces the severity of and/or slows the progression of one or more bacterial infections including but not limited to bacterial skin infections (e.g., Cellulitis, Folliculitis, Impetigo, Boils); foodborne illness such as nausea, vomiting, diarrhea, fever, chills and abdominal pain; sexually transmitted diseases such as chlamydia, gonorrhea, syphilis, bacterial vaginosis; and other bacterial infections such as bacterial meningitis, otitis media, urinary tract infection, and respiratory tract infections (e.g., sore throat, bronchitis, sinusitis).
  • bacterial skin infections e.g., Cellulitis, Folliculitis, Impetigo, Boils
  • foodborne illness such as nausea, vomiting, diarrhea, fever, chills and abdominal pain
  • sexually transmitted diseases such as chlamydia, gonorrhea, syphilis, bacterial vaginosis
  • other bacterial infections such as
  • the mammalian subjects in the methods described herein may have developed antibiotic resistance, where bacteria are no longer sensitive to an antibiotic medication such as one or more of Vancomycin, Ceftobiprole, Ceftaroline, Clindamycin, Dalbavancin, Daptomycin, Fusidic acid, Linezolid, Mupirocin (topical), Oritavancin, Tedizolid, Telavancin, Tigecycline, Aminoglycosides, Carbapenems, Ceftazidime, Cefepime, Ceftobiprole, Ceftolozane/tazobactam, Fluoroquinolones, Piperacillin/tazobactam, Ticarcillin/clavulanic acid, Linezolid, Streptogramins, Tigecycline, and Daptomycin.
  • an antibiotic medication such as one or more of Vancomycin, Ceftobiprole, Ceftaroline, Clindamycin, Dalbavancin, Dap
  • the method described herein further includes administering an antibiotic medication in addition to the COE(s), which may be simultaneously, concurrently, or sequentially administered.
  • antibiotic medication includes Vancomycin, Ceftobiprole, Ceftaroline, Clindamycin, Dalbavancin, Daptomycin, Fusidic acid, Linezolid, Mupirocin (topical), Oritavancin, Tedizolid, Telavancin, Tigecycline, Aminoglycosides, Carbapenems, Ceftazidime, Cefepime, Ceftobiprole, Ceftolozane/tazobactam, Fluoroquinolones, Piperacillin/tazobactam, Ticarcillin/clavulanic acid, Linezolid, Streptogramins, Tigecycline, and Daptomycin.
  • the safety of COEs is studied in a mouse model.
  • a range of drug doses is introduced into mice, for example, by intraperitoneal administration. Mice are monitored multiple times daily post-injection for toxicity evaluation. Compounds eliciting toxicity are generally re-tested at a lower dose or not pursued further. Compounds that are tolerated by mice in a dosage range that exhibits at least in vitro efficacy towards bacterial killing or inhibition are generally further tested for efficacy in bacterial clearance in infected mice. This can be pursued by subjecting the mice to virulent challenges with Gram-negative and Gram positive organisms.
  • Figure 1 shows a schematic of the synthesis of 3,5-bis((8- bromooctyl)oxy)benzaldehyde.
  • Figure 2 shows a schematic of the synthesis of l,3-bis((8-bromooctyl)oxy)-5- vinylbenzene from 3,5-bis((8-bromooctyl)oxy)benzaldehyde.
  • 3,5-bis((8-bromooctyl)oxy)benzaldehyde 300 mg, 0.577 mmol
  • potassium carbonate 87.5 mg, 0.634 mmol
  • methyltriphenylphosphonium bromide (227 mg, 0.634 mmol
  • Tetrahydrofuran (7 mL) was added to the flask and a reflux condenser was fitted. The mixture was refluxed for 24 hours under argon atmosphere. After cooling, the mixture was partitioned between ethyl acetate and brine. The aqueous phase was extracted an additional 3 times with ethyl acetate. The combined organic phase was washed with brine three times, dried over sodium sulfate, filtered, and concentrated by rotary evaporation. Column chromatography (1 : 15 ethyl acetate: hexane) afforded the pure product as a clear oil (220 mg, 74%).
  • Figure 3 depicts a schematic of the synthesis of (E)-l,2-bis(3,5-bis((8- bromooctyl)oxy)phenyl)ethene from 1 ,3-bis((8-bromooctyl)oxy)-5-vinylbenzene.
  • Figure 4 depicts a schematic of the synthesis of (E)-l,2-bis(3,5-bis((8- iodooctyl)oxy)phenyl)ethene from (E)-l ,2-bis(3,5-bis((8-bromooctyl)oxy)phenyl)ethene.
  • Figure 5 depicts a schematic of the synthesis of Formula B.
  • Figure 6 depicts a schematic of the synthesis of 3,5-bis((4- bromobutyl)oxy)benzaldehyde.
  • Figure 7 depicts the synthesis of 3,5-bis((4-iodobutyl)oxy)benzaldehyde.
  • Figure 8 depicts the synthesis of l,4-bis((E)-3,5-bis(4-iodobutoxy)styryl)benzene.
  • Sodium tert-butoxide (109 mg, 1.13 mmol) was added to a second flask under argon atmosphere, dissolved in 4 mL of anhydrous THF, and added to the reaction vessel slowly via syringe. The resulting mixture was kept at -78 °C for 20 mins before being allowed to warm temperature. After stirring for 16 hours, the mixture was partitioned between ethyl acetate and brine. The aqueous phase was extracted with three additional portions of ethyl acetate. The combined organic phase was washed with brine three times, dried over sodium sulfate, filtered, and concentrated by rotary evaporation.
  • Figure 9 depicts the synthesis of Formula F.
  • Figure 10 depicts the synthesis of Formula D.
  • Figure 11 depicts the synthesis of Formula C.
  • COE2-2N (20 mg, 0.141 mmol) was stirred in ⁇ l mL of pyridine at room temperature for 6 days. After 2 days, -10 mL methanol was added to aid dissolution. Volatiles were removed and the resulting solid was slurried in hexanes and filtered to collect a light orange solid, which was further dissolved in minimum amount of MeOH and added into 40 mL pentane. After centrifugation at 7000 rpm for 3 min, the resulting solid was dried in vacuo overnight. Formula C was afforded as a white solid (9 mg, 34.5 % yield).
  • Figure 12 depicts the synthesis of Formula E.
  • COE2-2N (54.2 mg, 0.05 mmol, 1.0 eq.) was dissolved in 15 mL dry THF and a large excess of N,N-dimethylhexylamine (0.3 mL, 20 eq.) was added. The resulting solution was stirred under argon at 45°C for 3 days. Some white solid precipitated out. Adding 5 mL MeOH, the solution was stirred for another 1 day. The solvent was removed via rotary evaporation. The resulting crude product was dissolved in minimum amount of MeOH and added into 40 mL ether. After centrifugation at 7000 rpm for 3 mins, the resulting solid was dried in vacuo for 5 hours.
  • MIC minimum inhibitory concentration
  • CLSI Clinical and Laboratory Standards Institute
  • bacteria were obtained from over-night culture ⁇ Staphylococci and Gram-negative bacteria) or after a 4 h incubation period (S. pneumoniae) in specified medium and diluted into same medium containing 2-fold serial dilutions of antibiotics.
  • MIC values were derived after 20 h incubation, and were the result of at least 6 independent determinations.
  • Table 1 shows the results from the MIC experiments determined by using different COEs.
  • the MIC study included Gram-negative strains Salmonella enterica Typhimurium (ST) ATCC 14028, E.
  • EC coli
  • PA Pseudomonas aeruginosa
  • KPN Klebsiella pneumoniae
  • the murine macrophage cell line RAW 264.7 was grown in DMEM supplemented with L-glutamine and 10% heat-inactivated fetal bovine serum in 5% C0 2 at 37°C in 75 cm 2 tissue culture flasks.
  • Cells were harvested using a sterile disposable cell scraper and plated at a density of 1 to 2 x 10 5 cells/mL in 2 mL culture medium in 24-well dishes and grown for 24h to approximately 90% confluence (2 to 4 x 10 5 cells/well). Media was removed and cells were washed with PBS. Drug was added at indicated concentrations in 1 mL volume of cell culture medium and cells were incubated for l 8h in 5% C0 2 at 37°C. Media was then removed, cells were washed with PBS, and cells were harvested using a sterile disposable cell scraper, diluted in trypan blue dye, and counted using a hemacytometer. The results are shown in Table 2
  • Resistant bacterial strains used for compound testing include methicillin-resistant S. aureus (MRSA), vancomycin resistant Enterococci (VRE) and various multi-drug resistant (MDR) strains commonly associated with hospital-acquired (nosocomial) infections, including, but not limited to A. baumannii, K. pnuemoniae, and E. cloacae.
  • MRSA methicillin-resistant S. aureus
  • VRE vancomycin resistant Enterococci
  • MDR multi-drug resistant
  • MIC minimum inhibitory concentration
  • E. coli K12 (ATCC 47076) and K. aerogenes (ATCC 13048) were cultured in LB medium at 37 °C and harvested at mid-log growth ( ⁇ 5h).
  • S. epidermidis (ATCC 14990) was cultured in BHI medium at 37 °C overnight before use. All bacteria were plated on agar and used for no more than 1 month to maintain activity. Lreezer-stock samples were preserved at -80 °C with 20% glycerin. The results with the bacteria of the paragraph following the procedure described herein is provided in Table 3.
  • the MIC was determined by measured absorbance at 600 nm. Column 11 is used as the control (bacteria without test article) and column 12 is the blank (no bacteria or test article). The lowest concentration that was found to show less than 10% relative growth was determined as MIC.
  • culture medium was pre-warmed to 37 °C.
  • the frozen tube was then removed from liquid nitrogen and placed into a 37 °C water bath and shaken gently to thaw the cell stock as quickly as possible. A small portion of the pre-warmed culture medium was added to the cell solution. The cell suspension was then centrifuged at 1000 r/min for 3 minutes. The supernatant was discarded and the cells were resuspended in fresh culture medium.
  • NIH 3T3 (ATCC CRL-1658) and Hep G2 (ATCC HB-8065) cells were cultured with DMEM + 10% FBS in 100 mm dishes.
  • J774 (ATCC TIB-67) cells were cultured with DMEM + 10% FBS in 100 mm dishes. Cells were lifted for subculture or testing when confluence reached -80% using a cell scraper.
  • RAW264.7 (ATCC TIB-71) cells were cultured with DMEM + 10% heat-inactivated FBS + 1% pen/strep in T75 flasks. Cells were lifted for subculture or testing when confluence reached -80% using a cell scraper.
  • Cells were lifted and resuspended in culture medium. The number of cells in the cell suspension was determined using an auto-cell counter: 10 pL of the cell suspension was mixed with 10 pL lx trypan blue (filtered with 0.2 pm PES filter) and the mixture was loaded onto a cell counting slide. Based on the concentration of viable cells, the cell suspension was further diluted to achieve the desired density.
  • Test articles were dissolved in IX PBS (or DMSO) to obtain stocks solution.
  • Stock solutions were pre-warmed before use.
  • Concentrated stock solutions were diluted to achieve 10X stocks of highest drug concentration (e.g., 1.28 mg/mL where 128 pg/mL is the desired highest test concentration).
  • Serial dilutions (2-fold) of the 10X solutions were made in sterile culture tubes by diluting in IX PBS (8 dilutions to yield 9 test concentrations).
  • 900 pL of culture media was added to each tube to obtain final drug solution containing 10% PBS (or less than 1% DMSO) for each experimental group.
  • test article solutions prepared in Step 3 100 pL of the test article solutions prepared in Step 3 were added to rows 2-7 of each column to obtain six replicates for each concentration. Plates were then incubated for 24 hours.
  • MTT solutions were prepared by dissolving commercial MTT powder in IX PBS to a concentration of 5 mg/mL. After passing through a 0.22 pm PES filter, the MTT solution was divided into 1 mL portions in sterile centrifuge tubes and stored at -20°C.
  • MTT stock solutions were removed from the freezer to thaw at room temperature. Before adding MTT solutions, cell cultures were visually inspected and imaged using a microscope (to use as a comparison with MTT results). 10 pL of the 5 mg/mL MTT solution was added to each well and the plate was incubated for 4 hours.
  • CD-l mouse red blood cells (IC05-3054, Innovative Research, Inc.) were stored at 4°C.
  • the cells were centrifuged at 500 g for 5 min. The supernatant was aspirated and the resulting pellets were resuspended in IX PBS. A second identical wash was performed. Resulting solutions were centrifuged at 800 g for 5 min and the cells were resuspended in IX PBS to yield a 5% volume/volume suspension.
  • COE stock solutions were prepared in IX PBS at 1.28 mg/m. 160 pL of COE stock solutions were added to 96-well (conical) plates and serially diluted (2-fold). A 40 pL portion of 5 % red blood cell solution was added to each well. The final concentrations of each COE were 16 pg/mF to 1024 pg/mF and the final concentration of the red blood cell was 1%. Blank PBS was used as a negative control and 1% Triton X-100 as a positive control.
  • the plate was incubated with gentle shaking for 1 hour at 37 °C and subsequently centrifuged for 5 min at 800g at room temperature. A 100 pL portion of the resulting supernatant was transferred to a flat-bottomed 96-well plate. Absorbance at 450 nm was measured on a plate reader. Percent hemolysis was determined by dividing background- corrected absorbance measurements by back-ground corrected measurements for 1% Triton X-100 (positive control for 100% hemolysis).
  • Formulae UU and O COEs are also active against both S. aureus (MRS A) and S. aureus (MSSA). As shown in Tables 5a-5d, several COEs described herein demonstrated efficacy against both Gram-negative and Gram-positive bacteria.
  • Formula E was more effective than Formula A, which highlights the important and surprising role of a substitution of methyl for hexyl in the quaternary ammonium groups responsible for controlling water solubility.
  • Applicant believes that the methyl for hexyl substitution fine-tunes drug association with the cell wall and/or membrane, thereby enhancing efficacy. Additional, considerations, with respect to solubility and efficacy, arise when comparing Formula C with Formula D; as the efficacy of Formula D could not be detected because of its low solubility.
  • Tables 5a-5d provide additional MIC data for compounds of described herein against a broader panel of bacterial species. This data further demonstrates the surprising biological activity resulting from the introduction of a larger alkyl group in place of a methyl on the trimethylammonium cationic group. For example, comparing the data for Formula T and Formula F clearly demonstrates the improved performance of the former against this panel of bacteria; whereby Formula T demonstrates lower MIC values against each species tested relative to Formula F.
  • data from Tables 5a-5d demonstrates an ability to modulate the efficacy of the compounds by changing the structure of the non-methyl group on the cationic moiety.
  • Formula R, Formula W and Formula Q are ethyl, propyl and butyl replacements, respectively on Formula F.
  • Formula R, Formula W and Formula Q also demonstrate improvements in efficacy across the panel tested, particularly the more lipophilic butyl derivative, Formula Q.
  • Formula R, Formula W and Formula Q show increasing efficacy as chain length increases, particularly against E. faecium.
  • Formula BB An additional comparison can be made between Formula BB and Formula AA, wherein the hexyl derivative (Formula BB) demonstrates increased efficacy relative to the butyl (Formula AA). These same two compounds had their cytotoxicity evaluated against the Hep G2 cell line ( Figure 13E) and the differences here should also be noted. While Formula AA demonstrated low cytotoxicity as shown by its IC50 of 637 pg/mL , Formula BB demonstrated high cytotoxicity as shown by its IC50 of 15 pg/mL. However, at concentrations that proved efficacious against bacterial species (0.25 - 4 pg/mL), Formula BB demonstrated cell viability of -90%.
  • Table 4 summarizes, by way of comparison, Formula E’s (methyl for hexyl alkyl substitution) consistently low (single digit) MIC values relative to a known antibiotic (AZT) and two trimethylammonium type COE compounds.
  • Klebsiella pneumoniae is streaked from frozen stocks onto Luria-Bertani (LB) agar plates and incubated overnight at 37°C. Single colonies are inoculated into LB broth and incubated overnight with shaking at 37°C. Bacteria are pelleted by centrifugation, washed, and suspended in sterile PBS. Intravenous (i.v.) injection into the retroorbital sinus of 1 to 2 xlO 8 cells (at least 20X LDso) is done in 100 pL volume. A dose of 20X LDso ensures that virtually all infected animals will undergo sepsis.
  • LB Luria-Bertani
  • Intravenous (i.v.) injection into the retroorbital sinus of 1 to 2 xlO 8 cells is done in 100 pL volume. A dose of 20X LD50 ensures that virtually all infected animals will undergo sepsis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2019/023411 2018-03-23 2019-03-21 Short conjugated oligoelectrolytes and uses thereof Ceased WO2019183381A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201980031110.5A CN112154212A (zh) 2018-03-23 2019-03-21 短共轭低聚电解质及其用途
US17/040,320 US11713318B2 (en) 2018-03-23 2019-03-21 Short conjugated oligoelectrolytes and uses thereof
SG11202009242RA SG11202009242RA (en) 2018-03-23 2019-03-21 Short conjugated oligoelectrolytes and uses thereof
EP19772107.9A EP3768849A4 (en) 2018-03-23 2019-03-21 SHORT CONJUGATED OLIGOELECTROLYTES AND THEIR USES
JP2020551278A JP7362131B2 (ja) 2018-03-23 2019-03-21 短い共役オリゴ電解質及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647181P 2018-03-23 2018-03-23
US62/647,181 2018-03-23

Publications (2)

Publication Number Publication Date
WO2019183381A2 true WO2019183381A2 (en) 2019-09-26
WO2019183381A3 WO2019183381A3 (en) 2020-04-23

Family

ID=67986375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/023411 Ceased WO2019183381A2 (en) 2018-03-23 2019-03-21 Short conjugated oligoelectrolytes and uses thereof

Country Status (6)

Country Link
US (1) US11713318B2 (https=)
EP (1) EP3768849A4 (https=)
JP (1) JP7362131B2 (https=)
CN (1) CN112154212A (https=)
SG (1) SG11202009242RA (https=)
WO (1) WO2019183381A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097077A1 (en) * 2019-11-15 2021-05-20 The Regents Of The University Of California Short conjugated oligoelectrolytes and antibiotics
WO2024228880A1 (en) * 2023-04-26 2024-11-07 The Regents Of The University Of California Antimicrobial conjugated oligoelectrolytes as broad-spectrum antibiotics
EP4387953A4 (en) * 2021-08-16 2025-08-20 Nat Univ Singapore DONOR-ACCEPTOR CONJUGATED OLIGOELECTROLYTES FOR CELL LABELING AND RELATED METHODS

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148293A1 (en) * 2023-01-05 2024-07-11 William Marsh Rice University Charged pi-conjugated molecules for the treatment of microbial infections
CN118021996B (zh) * 2024-01-16 2024-07-30 华南理工大学 一种抗菌包合材料及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB726260A (en) 1952-05-07 1955-03-16 Henri Morren Quaternary amino compounds and processes for the production thereof
ZA802160B (en) * 1979-04-11 1981-04-29 Ciba Geigy Ag Distyrylbiphenyls
ZA802159B (en) * 1979-04-11 1981-04-29 Ciba Geigy Ag Distyrylbenzenes
US4482680A (en) * 1981-09-15 1984-11-13 Dynapol Quaternary ammonium group-containing polymers having antimicrobial activity
US7094929B2 (en) 2003-03-14 2006-08-22 The Regents Of The University Of California Water-soluble distyrylbenzene chromophores for applications in optoelectronic technologies
WO2005056499A2 (en) 2003-12-04 2005-06-23 Northwestern University Oligo(p-phenylene vinylene) amphiphiles and methods for self-assembly
CN101035508A (zh) * 2004-08-09 2007-09-12 西巴特殊化学制品控股公司 荧光增白剂作为抗微生物剂的应用
WO2013020096A2 (en) 2011-08-03 2013-02-07 Stc.Unm Antimicrobial materials and methods
CN104224775B (zh) 2014-08-29 2017-03-15 国家纳米科学中心 一种包含四苯乙烯衍生物的药物组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097077A1 (en) * 2019-11-15 2021-05-20 The Regents Of The University Of California Short conjugated oligoelectrolytes and antibiotics
US20230019027A1 (en) * 2019-11-15 2023-01-19 The Regents Of The University Of California Short conjugated oligoelectrolytesand antibiotics
EP4387953A4 (en) * 2021-08-16 2025-08-20 Nat Univ Singapore DONOR-ACCEPTOR CONJUGATED OLIGOELECTROLYTES FOR CELL LABELING AND RELATED METHODS
WO2024228880A1 (en) * 2023-04-26 2024-11-07 The Regents Of The University Of California Antimicrobial conjugated oligoelectrolytes as broad-spectrum antibiotics

Also Published As

Publication number Publication date
JP2021519265A (ja) 2021-08-10
SG11202009242RA (en) 2020-10-29
CN112154212A (zh) 2020-12-29
US11713318B2 (en) 2023-08-01
JP7362131B2 (ja) 2023-10-17
WO2019183381A3 (en) 2020-04-23
EP3768849A2 (en) 2021-01-27
US20210017179A1 (en) 2021-01-21
EP3768849A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
EP3768849A2 (en) Short conjugated oligoelectrolytes and uses thereof
JP5737825B2 (ja) リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
US20190389819A1 (en) Processes for preparing oxathiazin-like compounds
PL173448B1 (pl) Nowe 9-[(chlorowcoacylo)amido]-6-demetylo-6-deoksytetracykliny ich sole organiczne, nieorganiczne lub kompleksy metali oraz sposób wytwarzania nowych 9-[(chlorowcoacylo)amido]-6-[demetylo-6-deoksytetracyklin, ich soli organicznych, nieorganicznych lub kompleksów metali
WO2021044437A1 (en) Olaparib co-crystals and process of preparation thereof
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
KR20240058958A (ko) 에라바사이클린의 결정질 형태
WO2020163479A1 (en) Antibiotic ammonium compounds and methods for the treatment of bacterial infections
CN114716384A (zh) 一种含有3,4-二氢嘧啶或嘧啶侧链的截短侧耳素类衍生物及其制备与应用
US20230019027A1 (en) Short conjugated oligoelectrolytesand antibiotics
US12054466B2 (en) Compounds for the treatment of clostridium difficile infection
CN115536716A (zh) 两性霉素b半合成衍生物及其制备方法和用途
EP4705278A1 (en) Antimicrobial conjugated oligoelectrolytes as broad-spectrum antibiotics
EP4232014A1 (en) Analogues of pentamidine and methods for treating infections
CN117209456B (zh) 一种苯基烷基醚类化合物及其制备方法和用途
KR102893769B1 (ko) 피롤 결찰의 옥사디아졸 유도체, 이의 제조방법 및 박테리아 감염 예방 또는 치료용 약학적 조성물
KR102680438B1 (ko) 콘테졸리드 아세포사밀의 약물 결정 및 이의 제조 방법 및 응용
ES2389070B1 (es) Derivados de policétidos dibenzofuránicos prenilados y su aplicación para el tratamiento de enfermedades infecciosas, parasitarias y tumores.
AU2020401174B2 (en) Lipophosphonoxins, their preparation and use
KR100344853B1 (ko) 항진균제로 유용한 신규 6,7-이치환-5,8-퀴놀린디온 유도체
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
EP3184516A1 (en) Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
US20220009967A1 (en) Isolation and Semi-Synthesis of Rufomycin Analogs
WO2021097159A1 (en) Method for preparing heteroleptic triarylbismuthanes and compounds produced by the same
JP2019064922A (ja) Ｃ−４”位置換マクロライド化合物の塩、それらの結晶形及びそれらの製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19772107

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020551278

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019772107

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19772107

Country of ref document: EP

Kind code of ref document: A2